2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jia Ruan, MD, PhD, discusses the evolving armamentarium in mantle cell lymphoma.
Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the evolving armamentarium in mantle cell lymphoma (MCL).
Chemoimmunotherapy has been a historical treatment approach for patients with MCL, says Ruan. However, over the past few years, treatment has evolved to incorporate effective, low-intensity, oral-based strategies, which are being used in the outpatient setting, Ruan explains. These therapies can be used in induction regimens or as treatment in the relapsed/refractory setting, Ruan says.
This shift has been revolutionary in the field of MCL, says Ruan. Therapy has become more convenient and accessible for the majority of patients, regardless of age and comorbidities.
This treatment approach will hopefully continue to benefit patients by extending remission duration and improving survival outcome for many years to come, Ruan concludes.